Literature DB >> 2413998

CAR-3, a monoclonal antibody-defined antigen expressed on human carcinomas.

M Prat, I Morra, G Bussolati, P M Comoglio.   

Abstract

Several monoclonal antibodies were raised against the human epidermoid carcinoma line A 431. The antibody produced by clone AR-3, when tested in enzyme-linked immunosorbent assay, was found to react with the cell line used as immunogen, the human gastric carcinoma line KATO III, the colon carcinoma line HT29, and the ovarian carcinoma line SW626. This monoclonal antibody was found unreactive when tested on human peripheral blood leukocytes or on a number of normal or neoplastic cell lines. The antibody precipitated a high-molecular-weight glycosylated component. When tested on paraffin sections by the avidin:biotin: peroxidase method, the AR-3 antibody stained pancreatic (6:7), gastric (11:14), ovarian (5:6), colon (4:8), endometrial (4:6), and cervical (4:7) carcinomas. A small minority of carcinomas of other organs was also stained. Sarcomas, lymphomas, and other tumors of nonepithelial origin were constantly negative. Staining of some normal epithelial cells was also observed. Among the fetal tissue tested, the antibody reacted with pancreatic ducts and the small intestine. The antibody recognized metastatic carcinoma cells in peritoneal effusions. On the basis of its tissue distribution, the antigenic determinant defined by the AR-3 monoclonal antibody was called CAR-3. The monoclonal AR-3 did not cross-react with partially purified preparations of carcinoembryonic antigen, gastrointestinal carcinoma antigen, or the human milk fat globule antigen. The AR-3 MAb appear, thus, to broaden the number of available reagents for histopathological diagnosis of carcinomas.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2413998

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Use of monoclonal antibodies in solid tumors diagnosis-the endometrial carcinoma.

Authors:  A Bartolazzi; M Mottolese; A Vocaturo; G Vocaturo; A Bigotti; M Prat; G A Giorgio Natali
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

2.  Recombinant proteins L and LG. Two new tools for purification of murine antibody fragments.

Authors:  R Vola; A Lombardi; L Tarditi; M Zaccolo; D Neri; L Björck; M Mariani
Journal:  Cell Biophys       Date:  1994

3.  Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines.

Authors:  L Cattel; L Delprino; P Brusa; F Dosio; P M Comoglio; M Prat
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Antitumour activity of a sterically blocked ricin immunotoxin on a human colorectal adenocarcinoma grafted subcutaneously in nude mice.

Authors:  P Brusa; F Dosio; F Pietribiasi; L Delprino; P Feraiorni; M Mariani; G Bussolati; L Cattel
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Blocked and not blocked whole-ricin-antibody immunotoxins: intraperitoneal therapy of human tumour xenografted in nude mice.

Authors:  P Brusa; F Pietribiasi; G Bussolati; F Dosio; R Arione; P M Comoglio; M Prat; L Cattel
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.